INDV Stock Forecast & Price Target

Indivior Pharmaceuticals has demonstrated robust growth in its Sublocade treatment, with an increase in patients treated by approximately 8% year-over-year, bringing the total to around 171,500 in the third quarter of 2025. The company has also expanded its prescriber base by 11%, indicating growing confidence and adoption of Sublocade among healthcare providers, which coincides with a positive revision of sales guidance for the drug to between $825 million and $845 million. With a strong sales increase of 15% for Sublocade in the latest quarter and an anticipated peak sales potential of $1.5 to $2.0 billion, Indivior appears well-positioned for sustainable long-term growth, supported by effective expense management and a commitment to research and development savings.

Indivior Pharmaceuticals is experiencing a significantly reduced commercial footprint for its key product, Sublocade, which has decreased from approximately 40 countries to just four. Furthermore, the discontinuation of commercial support for Opvee indicates challenges in product alignment and market synergy. As a result, consensus projections indicate a revenue decline of about 6.5% for 2026, raising concerns about the company's ability to sustain growth in the face of these strategic and operational setbacks.